Wikiwand AI

BriLife

Vaccine candidate against COVID-19 From Wikipedia, the free encyclopedia

BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[2][3][4][5] It was developed by the Israel Institute for Biological Research (IIBR).[2][6][7] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[8][9] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[10][4]

TargetSARS-CoV-2
Vaccine typeViral vector
Other namesBrilife
Routes of
administrationIntramuscular
Quick facts Vaccine description, Target ...
BriLife
Reuven Rivlin and the first person to receive the BriLife vaccine look at the viewer alongside two nurses. The flag of Israel sits in the background.
The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center.
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Other namesBrilife
Routes of
administration		Intramuscular
ATC code
  • None
Identifiers
CAS Number
Close

References

External links

Related Articles

Timelines

Top Qs

Fact Checks